A systems biology perspective on sVEGFR1: Its biological function, pathogenic role and therapeutic use

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 3, 2010, Pages 528-552

  Wu, Florence T H ^a   Stefanini, Marianne O ^a   Gabhann, Feilim Mac ^b   Kontos, Christopher D ^c   Annex, Brian H ^d   Popel, Aleksander S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Angiogenesis; Computational modelling; Molecular systems biology; Multi scale modelling; Neovascularization; Soluble fms like tyrosine kinase 1 (sFlt 1); Systems pharmacology; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ARTICLE; ATHEROSCLEROSIS; BIOLOGICAL MODEL; BLOOD; DRUG ANTAGONISM; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTEMS BIOLOGY;

ANGIOGENESIS INHIBITORS; ATHEROSCLEROSIS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SYSTEMS BIOLOGY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 77952593669     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00941.x     Document Type: Article

References (117)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005, 438:932-6.
2. Folkman J. Angiogenesis: an organizing principle for drug discovery. Nat Rev Drug Discov. 2007, 6:273-86.
3. Brown MD, Hudlicka O. Modulation of physiological angiogenesis in skeletal muscle by mechanical forces: involvement of VEGF and metalloproteinases. Angiogenesis. 2003, 6:1-14.
4. Williams JL, Weichert A, Zakrzewicz A. Differential gene and protein expression in abluminal sprouting and intraluminal splitting forms of angiogenesis. Clin Sci. 2006, 110:587-95.
5. Burri PH, Hlushchuk R, Djonov V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dyn. 2004, 231:474-88.
6. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003, 9:653-60.
7. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005, 438:967-74.
8. Testa U, Pannitteri G, Condorelli GL. Vascular endothelial growth factors in cardiovascular medicine. J Cardiovasc Med. 2008, 9:1190-221.
9. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008, 358:2039-49.
10. Verhoef C, de Wilt JHW, Verheul HMW. Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. Curr Pharm Des. 2006, 12:2623-30.
11. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000, 407:249-57.
12. Kommareddy S, Amiji M. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther. 2007, 14:488-98.
13. Gao Z, Wei Y, Yang P. Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts. Oral Oncol. 2007, 43:477-83.
14. Liu J, Li J, Su C. Soluble fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice. Acta Biochim Biophys Sin. 2007, 39:499-506.
15. Takei T, Sakai S, Ono T. Fabrication of endothelialized tube in collagen gel as starting point for self-developing capillary-like network to construct three-dimensional organs in vitro. Biotechnol Bioeng. 2006, 95:1-7.
16. Cai J, Jiang WG, Grant MB. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem. 2006, 281:3604-13.
17. Zhang Z, Zou W, Wang J. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antian giogenic gene, soluble flt-1. Mol Ther. 2005, 11:553-62.
18. Mahendra G, Kumar S, Isayeva T. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther. 2005, 12:26-34.
19. Ye C, Feng C, Wang S. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology. 2004, 145:817-22.
20. Mahasreshti PJ, Kataram M, Wang MH. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res. 2003, 9:2701-10.
21. Mahasreshti PJ, Navarro JG, Kataram M. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res. 2001, 7:2057-66.
22. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004, 4:423-36.
23. Collinson DJ, Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation. Eur J Vasc Endovasc Surg. 2004, 28:9-23.
24. Yla-Herttuala S, Rissanen TT, Vajanto I. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol. 2007, 49:1015-26.
25. Hazarika S, Dokun AO, Li Y. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res. 2007, 101:948-56.
26. Moulton KS. Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep. 2001, 3:225-33.
27. Blann AD, Belgore FM, McCollum CN. Vascular endothelial growth factor and its receptor, flt-l, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes. Clin Sci. 2002, 102:187-94.
28. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci. 2005, 109:227-41.
29. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans. 2003, 31:1171-7.
30. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005, 438:946-53.
31. Autiero M, Waltenberger J, Communi D. Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003, 9:936-43.
32. Maharaj ASR, Saint-Geniez M, Maldonado AE. Vascular endothelial growth factor localization in the adult. Am J Pathol. 2006, 168:639-48.
33. Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res. 2007, 74:100-13.
34. D'Amore PA. Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol. 2007, 171:14-8.
35. Lee S, Chen TT, Barber CL. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007, 130:691-703.
36. Pritchard-Jones RO, Dunn DB, Qiu Y. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer. 2007, 97:223-30.
37. Ladomery MR, Harper SJ, Bates DO. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett. 2007, 249:133-42.
38. Maynard SE, Min JY, Merchan J. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003, 111:649-58.
39. Levine RJ, Maynard SE, Qian C. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004, 350:672-83.
40. Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the " chicken-and-egg" question. Endocrinology. 2004, 145:4835-7.
41. Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered. J Clin Invest. 2003, 111:600-2.
42. Woolcock J, Hennessy A, Xu B. Soluble flt-1 as a diagnostic marker of pre-eclampsia. Aust N Z J Obstet Gynaecol. 2008, 48:64-70.
43. Diab AE, El-Behery MM, Ebrahiem MA. Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery doppler velocimetry. Int J Gynaecol Obstet. 2008, 102:146-51.
44. Widmer M, Villar J, Benigni A. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol. 2007, 109:168-80.
45. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004, 95:884-91.
46. Olsson AK, Dimberg A, Kreuger J. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006, 7:359-71.
47. Mac Gabhann F, Popel AS. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol. 2004, 286:H153-64.
48. Mac Gabhann F, Popel AS. Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophys Chem. 2007, 128:125-39.
49. Neagoe PE, Lemieux C, Sirois MG. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem. 2005, 280:9904-12.
50. Kreuger J, Spillmann D, Li J. Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol. 2006, 174:323-7.
51. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol. 2005, 6:646-56.
52. Jenniskens GJ, Veerkamp JH, van Kuppevelt TH. Heparan sulfates in skeletal muscle development and physiology. J Cell Physiol. 2006, 206:283-94.
53. Wijelath ES, Rahman S, Namekata M. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res. 2006, 99:853-60.
54. Guttmann-Raviv N, Kessler O, Shraga-Heled N. The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett. 2006, 231:1-11.
55. Pan Q, Chathery Y, Wu Y. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem. 2007, 282:24049-56.
56. Mac Gabhann F, Popel AS. Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol. 2007, 292:459-74.
57. Soker S, Miao HQ, Nomi M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem. 2002, 85:357-68.
58. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993, 90:10705-9.
59. Hornig C, Barleon B, Ahmad S. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest. 2000, 80:443-54.
60. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996, 226:324-8.
61. Bando H, Weich HA, Brokelmann M. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer. 2005, 92:553-61.
62. Jaroszewicz J, Januszkiewicz M, Flisiak R. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment. Cytokine. 2008, 44:14-7.
63. Shapiro NI, Yano K, Okada H. A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis. Shock. 2008, 29:452-7.
64. Gehlbach P, Demetriades AM, Yamamoto S. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther. 2003, 14:129-41.
65. Ebos JM, Bocci G, Man S. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res. 2004, 2:315-26.
66. Aref S, El Sherbiny M, Goda T. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology. 2005, 10:131-4.
67. Lorquet S, Berndt S, Blacher S. Implication of soluble receptors of VEGF, sVEGFR-1 and sVEGFR-2, in angiogenesis. Am J Reprod Immunol. 2008, 60:85.
68. Gagnon ML, Bielenberg DR, Gechtman Z. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc Natl Acad Sci USA. 2000, 97:2573-8.
69. Ambati BK, Nozaki M, Singh N. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006, 443:993-7.
70. Banks RE, Forbes MA, Searles J. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, flt-1. Mol Hum Reprod. 1998, 4:377-86.
71. Heydarian M, McCaffrey T, Florea L. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta. 2009, 30:250-5.
72. Thomas CP, Andrews JI, Liu KZ. Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. FASEB J. 2007, 21:3885-95.
73. Sela S, Itin A, Natanson-Yaron S. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res. 2008, 102:1566-74.
74. Thomas CP, Andrews JI, Raikwar NS. A recently evolved novel trophoblast-enriched sFlt1 variant is upregulated in hypoxia and in preeclampsia. J Clin Endocrinol Metab. 2009
75. Rahimi N, Golde TE, Meyer RD. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer Res. 2009
76. Barleon B, Totzke F, Herzog C. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem. 1997, 272:10382-8.
77. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem. 2000, 275:26690-5.
78. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci. 2006, 63:601-15.
79. Ambati BK, Patterson E, Jani P. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol. 2007, 91:505-8.
80. Kim NH, Oh JH, Seo JA. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int. 2005, 67:167-77.
81. Kumai Y, Ooboshi H, Ibayashi S. Postischemic gene transfer of soluble flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability. J Cereb Blood Flow Metab. 2007, 27:1152-60.
82. Tsao P, Chan F, Wei S. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med. 2007, 35:1955-60.
83. Sako A, Kitayama J, Koyama H. Transduction of soluble flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res. 2004, 64:3624-8.
84. Rota R, Riccioni T, Zaccarini M. Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med. 2004, 6:992-991002.
85. Afuwape AO, Feldmann M, Paleolog EM. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther. 2003, 10:1950-60.
86. Miotla J, Maciewicz R, Kendrew J. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest. 2000, 80:1195-205.
87. Hornig C, Weich HA. Soluble VEGF receptors. Angiogenesis. 1999, 3:33-9.
88. Kappas NC, Zeng G, Chappell JC. The VEGF receptor flt-1 spatially modulates flk-1 signaling and blood vessel branching. J Cell Biol. 2008, 181:847-58.
89. Wu FT, Stefanini MO, Mac Gabhann F. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS ONE. 2009, 4:e5108.
90. Wu FT, Stefanini MO, Mac Gabhann F. A computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport. Physiol Genomics. 2009, 38:29-41.
91. Lamszus K, Ulbricht U, Matschke J. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res. 2003, 9:1399-405.
92. Clavel G, Bessis N, Lemeiter D. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol. 2007, 124:158-64.
93. Chang YT, Chang MC, Wei SC. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas. 2008, 37:145-50.
94. Bailey AP, Shparago M, Gu JW. Exercise increases soluble vascular endothelial growth factor receptor-1 (sFlt-1) in circulation of healthy volunteers. Med Sci Monit. 2006, 12:CR45-50.
95. Felmeden DC, Spencer CGC, Blann AD. Physical activity in relation to indices of endothelial function and angiogenesis factors in hypertension: a substudy of the anglo-scandinavian cardiac outcomes trial (ASCOT). J Intern Med. 2003, 253:81-91.
96. Chung NA, Lydakis C, Belgore F. Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart. 2003, 89:1411-5.
97. Lip PL, Belgore F, Blann AD. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci. 2000, 41:2115-9.
98. Lip PL, Felmeden DC, Blann AD. Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von willebrand factor in glaucoma. Br J Ophthalmol. 2002, 86:1299-302.
99. Findley CM, Mitchell RG, Duscha BD. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol. 2008, 52:387-93.
100. Makin AJ, Chung NA, Silverman SH. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis. Clin Sci. 2003, 104:397-404.
101. Belgore FM, Blann AD, Lip GY. Measurement of free and complexed soluble vascular endothelial growth factor receptor, flt-1, in fluid samples: development and application of two new immunoassays. Clin Sci. 2001, 100:567-75.
102. Yano K, Liaw PC, Mullington JM. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med. 2006, 203:1447-58.
103. Yano K, Okada Y, Beldi G. Elevated levels of placental growth factor represent an adaptive host response in sepsis. J Exp Med. 2008, 205:2623-31.
104. Mac Gabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation. 2008, 15:715-38.
105. Qutub AA, Mac Gabhann F, Karagiannis ED. Multiscale models of angiogenesis. IEEE Eng Med Biol Mag. 2009, 28:14-31.
106. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001, 47:617-23.
107. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007, 97:978-85.
108. Tamkun JW, Hynes RO. Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem. 1983, 258:4641-7.
109. Mosher DF. Physiology of fibronectin. Annu Rev Med. 1984, 35:561-75.
110. Taylor RN, Crombleholme WR, Friedman SA. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol. 1991, 165:895-901.
111. Mitsi M, Hong Z, Costello CE. Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites. Biochemistry. 2006, 45:10319-28.
112. Verheul HM, Lolkema MP, Qian DZ. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res. 2007, 13:5341-7.
113. Autiero M, Luttun A, Tjwa M. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003, 1:1356-70.
114. Gavin TP, Ruster RS, Carrithers JA. No difference in the skeletal muscle angiogenic response to aerobic exercise training between young and aged men. J Physiol. 2007, 585:231-9.
115. Hoffner L, Nielsen JJ, Langberg H. Exercise but not prostanoids enhance levels of vascular endothelial growth factor and other proliferative agents in human skeletal muscle interstitium. J Physiol. 2003, 550:217-25.
116. Arner P. Microdialysis: use in human exercise studies. Proc Nutr Soc. 1999, 58:913-7.
117. Kim WJ, Yockman JW, Jeong JH. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. J Control Release. 2006, 114:381-8.